TESTING (2017) — Trial Summary

TESTING (2017): Randomized, double-blind, placebo-controlled trial of oral methylprednisolone versus placebo in adults with IgA nephropathy and proteinuria ≥1 g/day despite optimized RAS blockade (NCT01560052). Primary composite: 40% decline in eGFR, end-stage kidney disease, or death due to kidney

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.